147 related articles for article (PubMed ID: 22028347)
21. Triptorelin for Fertility Preservation in Adolescents Treated With Chemotherapy for Cancer.
Meli M; Caruso-Nicoletti M; La Spina M; Nigro LL; Samperi P; D'Amico S; Bellia F; Miraglia V; Licciardello M; Cannata E; Marino S; Cimino C; Puglisi F; Valvo LL; Pezzulla A; Russo G; Di Cataldo A
J Pediatr Hematol Oncol; 2018 May; 40(4):269-276. PubMed ID: 29620680
[TBL] [Abstract][Full Text] [Related]
22. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
[TBL] [Abstract][Full Text] [Related]
23. Trying to reduce ovarian damage in patients with Hodgkin lymphoma using GnRH agonists?
Oktay K; Sonmezer M; Barad D; Gleicher N
Fertil Steril; 2009 Jan; 91(1):298-9; author reply 299. PubMed ID: 19046580
[No Abstract] [Full Text] [Related]
24. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis.
Bedaiwy MA; Abou-Setta AM; Desai N; Hurd W; Starks D; El-Nashar SA; Al-Inany HG; Falcone T
Fertil Steril; 2011 Mar; 95(3):906-14.e1-4. PubMed ID: 21145541
[TBL] [Abstract][Full Text] [Related]
25. [Prevention of anticancer drug-induced premature ovarian failure].
Tanaka T; Utsunomiya T; Umesaki N
Nihon Rinsho; 2006 Apr; 64 Suppl 4():101-11. PubMed ID: 16689293
[No Abstract] [Full Text] [Related]
26. [Premature ovarian failure in patients affected by oncohematological disease].
Marchesoni D; Driul L; Fruscalzo A; Santuz M; Calcagno A; Ianni A; Geromin A; Fanin R
Minerva Ginecol; 2005 Oct; 57(5):545-50. PubMed ID: 16205599
[TBL] [Abstract][Full Text] [Related]
27. Comment on GnRH analogue cotreatment with chemotherapy for preservation of ovarian function.
Balkenende E; Dahhan T; van der Veen F; Goddijn M
Fertil Steril; 2011 Oct; 96(4):e155-6; author reply e157. PubMed ID: 21862002
[No Abstract] [Full Text] [Related]
28. 3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience.
Caruso M; Castiglione G; Aiello R; Alí M; Chiarenza M; Dimarco R; Fallica G; Di Leo MG; Sanó MV; Taibi E; Zacchia A; Miano E; Caruso F
Future Oncol; 2015; 11(23):3109-12. PubMed ID: 26544787
[No Abstract] [Full Text] [Related]
29. [Premature ovarian failure after chemotherapy for breast cancer].
Mathelin C; Brettes JP; Diemunsch P
Bull Cancer; 2008 Apr; 95(4):403-12. PubMed ID: 18495569
[TBL] [Abstract][Full Text] [Related]
30. Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy.
Kim HJ; Lee MH; Lee JE; Park S; Lee ES; Kang YJ; Shin HN; Kim SI; Lee JH; Im SA; Ahn SH; Lee KS; Sohn J; Kim S; Nam SJ; Han W
Clin Breast Cancer; 2018 Oct; 18(5):e1165-e1172. PubMed ID: 29843988
[TBL] [Abstract][Full Text] [Related]
31. Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer.
Moore HC
Curr Oncol Rep; 2000 Nov; 2(6):587-93. PubMed ID: 11122897
[TBL] [Abstract][Full Text] [Related]
32. Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy?
Partridge AH
J Clin Oncol; 2012 Feb; 30(5):479-81. PubMed ID: 22231046
[No Abstract] [Full Text] [Related]
33. Strategies for fertility preservation in young early breast cancer patients.
Tomasi-Cont N; Lambertini M; Hulsbosch S; Peccatori AF; Amant F
Breast; 2014 Oct; 23(5):503-10. PubMed ID: 24934638
[TBL] [Abstract][Full Text] [Related]
34. What is new in reproductive endocrinology?: best articles from the past year.
Liu JH
Obstet Gynecol; 2012 May; 119(5):1052-4. PubMed ID: 22525920
[No Abstract] [Full Text] [Related]
35. Gonadotropin-releasing hormone agonist for preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
Blumenfeld Z
J Clin Oncol; 2012 Sep; 30(26):3310; author reply 3312-3. PubMed ID: 22649145
[No Abstract] [Full Text] [Related]
36. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
Frampton JE
Drugs; 2017 Dec; 77(18):2037-2048. PubMed ID: 29177573
[TBL] [Abstract][Full Text] [Related]
37. Comment on: sexual and fertility adverse effects associated with chemotherapy treatment in women.
Blumenfeld Z
Expert Opin Drug Saf; 2014 Sep; 13(9):1283-5. PubMed ID: 25105679
[No Abstract] [Full Text] [Related]
38. Ovulation induction and luteal support with GnRH agonist in patients at high risk for hyperstimulation syndrome.
Fusi FM; Arnoldi M; Bosisio C; Lombardo G; Ferrario M; Zanga L; Galimberti A; Capitanio E
Gynecol Endocrinol; 2015; 31(9):693-7. PubMed ID: 26527503
[TBL] [Abstract][Full Text] [Related]
39. [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].
Gris-Martínez JM; Trillo-Urrutia L; Gómez-Cabeza JJ; Encabo-Duró G
Med Clin (Barc); 2016 Feb; 146(3):97-103. PubMed ID: 26194532
[TBL] [Abstract][Full Text] [Related]
40. Response to "Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury".
Somers EC; Christman GM; Fisseha S; Marder W; McCune WJ
Oncologist; 2008 May; 13(5):613-4; author reply 615-7. PubMed ID: 18581656
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
